Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Heart failure hope: weight loss drug trial targets obese patients

NCT ID NCT05371496

ENROLLING_BY_INVITATION Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

Summary

This study is testing if a medication called semaglutide, which is used for weight loss, can improve heart function and symptoms in obese patients with a specific type of heart failure. Researchers will give the drug or a placebo to 81 participants to see if aggressive weight loss helps the heart work better during exercise. The main goal is to see if it lowers pressure in the heart's blood vessels when patients are active.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

Conditions

Explore the condition pages connected to this study.